Protara Therapeutics (NASDAQ:TARA) Announces Earnings Results

Protara Therapeutics (NASDAQ:TARA) issued its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.03), FiscalAI reports.

Protara Therapeutics Price Performance

Shares of NASDAQ TARA opened at $3.89 on Thursday. The firm’s 50-day moving average is $4.04 and its two-hundred day moving average is $5.04. The company has a market capitalization of $218.62 million, a PE ratio of -2.88 and a beta of 1.50. Protara Therapeutics has a 12-month low of $2.97 and a 12-month high of $7.82.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Finally, Oppenheimer lifted their price objective on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TARA. Persistent Asset Partners Ltd acquired a new stake in Protara Therapeutics during the 4th quarter valued at $57,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Protara Therapeutics during the fourth quarter valued at $59,000. AQR Capital Management LLC purchased a new stake in Protara Therapeutics during the 4th quarter worth about $78,000. JPMorgan Chase & Co. acquired a new position in Protara Therapeutics in the 2nd quarter valued at about $46,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Protara Therapeutics in the 2nd quarter valued at about $53,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.